Received Apr 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | A003663 | OT |
vaccine was inadvertently administered to a patient that was 14.5 weeks pregnant; No symptomatic events were reported; This spontaneous prospective pregnancy report was received from a nurse and refers to a 21-year-old female patient. The patient's medical history was not reported. Concurrent conditions included sickle-cell trait. Concomitant medications included ondansetron (ZOFRAN) and minerals nos (+) vitamins nos (PRENATAL VITAMINS). She had no drug reactions or allergies. On an unknown pregnancy conception date (estimated as approximately 26-JAN-2026), the patient became pregnant, with last menstrual period (LMP) date estimated as approximately 12-JAN-2026. This pregnancy involved 1 fetus (by default). Pregnancy due date was not reported but calculated as approximately 19-OCT-2026. On an unspecified date in March 2026, the patient underwent obstetric laboratory tests (reported as "OB-labs"; results not reported). On 24-APR-2026, the 14.5-week-pregnant patient was inadvertently vaccinated with 1st dose of human papillomavirus 9-valent vaccine, recombinant (GARDASIL 9) suspension for injection at a total dose of 0.5 mL, administered intramuscularly, lot #A003663, expiration date: 11-DEC-2026, for prophylaxis (anatomical location was not reported) (Exposure during pregnancy). The pregnancy outcome was considered as pregnancy ongoing. Fetal outcome was unknown. No symptomatic events were reported (No adverse event).
Sickle-cell trait
Zofran; pre-natal vitamins